Last updated: November 24, 2009
Sponsor: Gilead Sciences
Overall Status: Completed
Phase
3
Condition
Angina
Heart Disease
Cardiac Disease
Treatment
N/AClinical Study ID
NCT00091429
CVT 3037
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Eligible patients must have a diagnosis of chronic angina, with documented evidence of coronary artery disease or prior myocardial infarction, in addition to other study entry criteria. Prior to entering the study, patients will be required to have had at least two weeks of treatment with amlodipine 10 mg daily, with the discontinuation of all other anti-anginal therapy for the duration of the study.
Study Design
Total Participants: 500
Study Start date:
August 01, 2004
Estimated Completion Date:
February 28, 2005